Asia branded business decline due to shipment push-outs
Asia branded sales declined 8% YoY in Q2 due to supplies pushed to next quarter; recovery depends on execution.
AJANTPHARM / Q2-FY24 / risks
Keep the risk register visible.
Ajanta Pharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Africa market slowdown may persist
Africa branded business saw a slowdown in the market over the last 4-5 months; growth recovery is uncertain.
Chantix launch timing uncertain
Chantix launch is delayed to Q4 FY24 or Q1 FY25; any further delay could impact US revenue expectations.
Price erosion in US generics remains high single-digit
Management confirmed high single-digit price erosion in US base portfolio, which could pressure margins if volumes don't compensate.